Safety and biodistribution of exosomes derived from human induced pluripotent stem cells

Zhewei Gu, Zhiyu Yin, Pengbo Song, Ying Wu, Ying He, Maoshu Zhu, Zhengxin Wu, Sicheng Zhao, Hongri Huang, Huihuang Wang, Cailing Tong, Zhongquan QiFrontiers in Bioengineering and Biotechnology 2022 · DOI

Abstract

As a new cell-free therapy, exosomes have provided new ideas for the treatment of various diseases. Human induced pluripotent stem cells (hiPSCs) cannot be used in clinical trials because of tumorigenicity, but the exosomes derived from hiPSCs may combine the advantages of iPSC pluripotency and the nanoscale size of exosomes while avoiding tumorigenicity. Currently, the safety and biodistribution of hiPSC-exosomes in vivo are unclear. Here, we investigated the effects of hiPSC-exosomes on hemolysis, DNA damage, and cytotoxicity through cell experiments. We also explored the safety of vein injection of hiPSC-exosomes in rabbits and rats. Differences in organ distribution after nasal administration were compared in normal and Parkinson's disease model mice. This study may provide support for clinical therapy and research of intravenous and nasal administration of hiPSC-exosomes.

Introduction

The discovery of human induced pluripotent stem cells (hiPSCs) revolutionized regenerative medicine, offering a way to create patient-specific tissues for treating diseases like Parkinson’s. However, their clinical application is stalled by a major safety hurdle: hiPSCs can differentiate into unwanted cell types or form tumors once transplanted.

Exosomes—nanoscale vesicles secreted by cells—emerge as a "best of both worlds" solution. They carry the therapeutic "instructions" (miRNAs, proteins) of their parent stem cells but, because they are not alive and cannot replicate, they do not form tumors. While promising, the basic safety profile and biodistribution of these particles after administration remained largely unknown. This study fills that gap by rigorously testing hiPSC-derived exosomes (hiPSC-exos) in various animal models.

Methods and Characterization

The researchers established a robust pipeline for producing and characterizing hiPSC-exos. First, the source hiPSCs were verified for pluripotency and genetic stability to ensure the quality and consistency of the derived vesicles.

Immunofluorescence staining confirming the expression of pluripotency markers Oct4, Tra-1-60, Nanog, and SOX2 in the source hiPSCs.
Karyotype analysis showing a normal 46,XY chromosomal complement in the hiPSCs used for exosome production.

Exosomes were isolated from hiPSC culture supernatants using a multi-step process involving filtration and high-speed ultracentrifugation. Characterization included Transmission Electron Microscopy (TEM) for morphology, Nanoparticle Tracking Analysis (NTA) for size (mean diameter of 143.5 nm), and Western Blotting for exosomal markers like CD9 and TSG101.

Safety was assessed through in vitro tests for hemolysis, DNA damage (alkaline comet assay), and cytotoxicity in RAW264.7 macrophages. In vivo safety was evaluated via local irritation tests in rabbits and systemic toxicity in Sprague-Dawley rats. Finally, biodistribution was tracked in C57 mice, including a 6-hydroxydopamine-induced Parkinson’s disease (PD) model, using intranasal administration.

Key Results

Safety Profile

The hiPSC-exos demonstrated an excellent safety profile. No significant hemolysis was observed, and the comet assay showed no DNA tailing, indicating zero DNA damage. In macrophages, the exosomes slightly promoted growth rather than causing cytotoxicity, suggesting they carry pro-survival signals inherited from their pluripotent parent cells. Systemically, all blood indexes (WBC, RBC, Hemoglobin) and biochemical markers for liver and kidney function in rats remained within healthy reference ranges after both intravenous and nasal administration.

Biodistribution and Targeting

Fluorescence imaging showed that exosomes remained detectable in the body for over 48 hours. A key finding was the efficacy of the nasal route in bypassing the blood-brain barrier. Notably, exosomes accumulated more significantly in the brains of PD model mice than in healthy controls. This suggests that diseased or inflamed brain tissue might actively recruit or better retain these therapeutic vesicles, enhancing their potential for targeted delivery.

Discussion and Conclusion

Despite being derived from human cells and injected into different species (rabbits and rats), the exosomes did not trigger significant immune rejection or organ damage. This highlights their potential as a universal, cell-free therapeutic platform. The targeted accumulation in diseased brain tissue via nasal delivery offers a non-invasive strategy for treating neurodegenerative disorders like Parkinson's disease.

While the safety profile is promising, long-term chronic toxicity studies and a more detailed mapping of metabolic pathways are needed before clinical translation. Future research should also elucidate the specific molecular mechanisms—likely involving miRNAs and proteins—by which these exosomes exert their therapeutic effects.

Summary updated

Abstract

As a new cell-free therapy, exosomes have provided new ideas for the treatment of various diseases. Human induced pluripotent stem cells (hiPSCs) cannot be used in clinical trials because of tumorigenicity, but the exosomes derived from hiPSCs may combine the advantages of iPSC pluripotency and the nanoscale size of exosomes while avoiding tumorigenicity. Currently, the safety and biodistribution of hiPSC-exosomes <i>in vivo</i> are unclear. Here, we investigated the effects of hiPSC-exosomes on hemolysis, DNA damage, and cytotoxicity through cell experiments. We also explored the safety of vein injection of hiPSC-exosomes in rabbits and rats. Differences in organ distribution after nasal administration were compared in normal and Parkinson's disease model mice. This study may provide support for clinical therapy and research of intravenous and nasal administration of hiPSC-exosomes.
BibTeX
@inproceedings{gu2022safety,
  author = {Zhewei Gu and Zhiyu Yin and Pengbo Song and Ying Wu and Ying He and Maoshu Zhu and Zhengxin Wu and Sicheng Zhao and Hongri Huang and Huihuang Wang and Cailing Tong and Zhongquan Qi},
  title = {{Safety and biodistribution of exosomes derived from human induced pluripotent stem cells}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2022},
  doi = {10.3389/fbioe.2022.949724},
}
Figure